Modeling the economic value of a Chagas' disease therapeutic vaccine

Bruce Y. Lee, Kristina M. Bacon, Angela R. Wateska, Maria Elena Bottazzi, Eric Dumonteil, Peter J. Hotez

Research output: Contribution to journalArticle

Abstract

The health burden of Chagas' disease (resulting from Trypanosoma cruzi infection) in Latin America (estimated to outweigh that of malaria by 5-fold and affect 2-6 million people in Mexico alone) has motivated development of therapeutic vaccines to prevent infection progression to severe disease. Our economic model for a Chagas' therapeutic vaccine in Mexico suggests that a vaccine would be highly cost-effective and in many cases economically dominant (providing both cost savings and health benefits) throughout a range of protection durations, severe adverse event risk and dosing regimens and would be most likely to provide a positive return on investment if the vaccine prevented (rather than delayed) the onset of cardiomyopathy.

Original languageEnglish (US)
Pages (from-to)1293-1301
Number of pages9
JournalHuman Vaccines and Immunotherapeutics
Volume8
Issue number9
DOIs
StatePublished - Sep 1 2012
Externally publishedYes

Keywords

  • Chagas' disease
  • Chagas' therapeutic vaccine
  • Cost-effectiveness
  • Mexico
  • Trypanosoma cruzi

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pharmacology

Fingerprint Dive into the research topics of 'Modeling the economic value of a Chagas' disease therapeutic vaccine'. Together they form a unique fingerprint.

  • Cite this

    Lee, B. Y., Bacon, K. M., Wateska, A. R., Bottazzi, M. E., Dumonteil, E., & Hotez, P. J. (2012). Modeling the economic value of a Chagas' disease therapeutic vaccine. Human Vaccines and Immunotherapeutics, 8(9), 1293-1301. https://doi.org/10.4161/hv.20966